NCT00215670View on ClinicalTrials.gov

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

May 31, 2006

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

pegaptanib sodium (Macugen)

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Eyetech Pharmaceuticals

INDUSTRY